Multiple Myeloma — Expanded Access Programs

• Study on Early and Late Consolidation/Maintenance Therapy for Multiple Myeloma — University of Arkansas
• Long-term Study for People Previously Treated with Ciltacabtagene Autoleucel — Janssen Research & Development, LLC
• Phase II Study of Daratumumab, Clarithromycin, Pomalidomide, and Dexamethasone for Multiple Myeloma Patients Previously Treated with Daratumumab — Weill Medical College of Cornell University
• Phase III Study on the Safety and Effectiveness of BL-8040 and G-CSF for Stem Cell Mobilization in Multiple Myeloma Patients — BioLineRx, Ltd.
• Study Comparing Anitocabtagene Autoleucel to Standard Therapy in Patients with Relapsed or Refractory Multiple Myeloma — Kite, A Gilead Company
• Study Comparing CAR-T Therapy JNJ-68284528 with Standard Treatments for Relapsed Multiple Myeloma — Janssen Research & Development, LLC
• Study Comparing JNJ-79635322 with a BCMAxCD3 Antibody for Treating Relapsed or Refractory Multiple Myeloma — Janssen Research & Development, LLC
• Study Comparing JNJ-79635322 and Teclistamab for Treating Relapsed or Refractory Multiple Myeloma — Janssen Research & Development, LLC
• Study on the Effectiveness and Safety of Cevostamab in Patients with Relapsed or Hard-to-Treat Multiple Myeloma — Hoffmann-La Roche
• Study on Using Tocilizumab to Prevent Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma — Janssen Research & Development, LLC
• Study Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Newly Diagnosed Multiple Myeloma Patients Ineligible for Stem Cell Transplant — GlaxoSmithKline
• Study Comparing Two Treatment Approaches for Newly Diagnosed Multiple Myeloma Without Planned Stem Cell Transplant — Janssen Research & Development, LLC
• Study on Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab for Patients with Relapsed or Refractory Myeloma Undergoing Stem Cell Transplant — Memorial Sloan Kettering Cancer Center
• Study on Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone for Treating Relapsed or Resistant Multiple Myeloma — Hackensack Meridian Health
• Study on Ciltacabtagene Autoleucel and Talquetamab for Treating High-Risk Multiple Myeloma — Janssen Research & Development, LLC
• Study on Combination Therapy with Venetoclax, Daratumumab, and Dexamethasone (With and Without Bortezomib) for Patients with Relapsed or Hard-to-Treat Multiple Myeloma — AbbVie
• Study on CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Kidney Disease Related to Monoclonal Gammopathy — Memorial Sloan Kettering Cancer Center
• Study on Dara-RVd and Teclistamab-RVd for People with Multiple Myeloma — Memorial Sloan Kettering Cancer Center
• Study on Daratumumab for Patients with Multiple Myeloma or Smoldering Multiple Myeloma — Janssen Research & Development, LLC
• Study on Daratumumab for Patients with Newly Diagnosed Multiple Myeloma — Memorial Sloan Kettering Cancer Center
• Study Comparing Two Treatment Approaches for Newly Diagnosed Multiple Myeloma: DVRd with Ciltacabtagene Autoleucel vs. DVRd with Stem Cell Transplant — Stichting European Myeloma Network
• Study on Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly-Diagnosed Multiple Myeloma Patients — University of Miami
• Study on Different Treatment Sequences for Newly Diagnosed Standard-Risk Multiple Myeloma — Janssen Research & Development, LLC
• Study on Elotuzumab with Pomalidomide, Bortezomib, and Dexamethasone for Treating Relapsed Multiple Myeloma — Massachusetts General Hospital
• Study on Elranatamab and Cyclophosphamide for Treating Multiple Myeloma — Memorial Sloan Kettering Cancer Center
• Study on Elranatamab for Patients with Relapsed or Refractory Multiple Myeloma — SCRI Development Innovations, LLC
• Study on Quality of Life in People with Multiple Myeloma Receiving Daratumumab or Lenalidomide — Memorial Sloan Kettering Cancer Center
• Study on CAR-T Cell Therapy JNJ-68284528 for Treating Multiple Myeloma — Janssen Research & Development, LLC
• Study on JNJ-79635322 for Patients with Relapsed or Refractory Multiple Myeloma — Janssen Research & Development, LLC
• Study on Lenalidomide and CC-486 with Radiation Therapy for Patients with Plasmacytoma — Memorial Sloan Kettering Cancer Center
• Study on Melphalan With or Without Siltuximab for Multiple Myeloma Patients Undergoing Stem Cell Transplant — Memorial Sloan Kettering Cancer Center
• Study on Talquetamab for People with Multiple Myeloma After BCMA CAR T-Cell Therapy — Memorial Sloan Kettering Cancer Center
• Study on Teclistamab and Talquetamab Combinations with Daratumumab and Lenalidomide for Newly Diagnosed Multiple Myeloma — Janssen Research & Development, LLC
• Study Comparing Teclistamab with Daratumumab and Other Treatments for Relapsed or Refractory Multiple Myeloma — Janssen Research & Development, LLC
• Study on the Combination of Talquetamab and Teclistamab for Treating Relapsed or Hard-to-Treat Multiple Myeloma — Janssen Research & Development, LLC
• Study on TNB-383B for Patients with Relapsed or Hard-to-Treat Multiple Myeloma — AbbVie
• Study on Whether Ide-cel (bb2121) Can Be Made from People with Multiple Myeloma Who Have Had a Blood Cell Transplant — Memorial Sloan Kettering Cancer Center
• Study on Comparing Etentamig and Daratumumab with Standard Treatment for Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant — AbbVie
• Study on the Safety and Effects of ABBV-453 Alone or with Other Myeloma Treatments in Adults with Multiple Myeloma — AbbVie
• Study on Etentamig for Treating Multiple Myeloma, Alone or with Other Medications — AbbVie
• Study Comparing Iberdomide and Lenalidomide Maintenance Therapy After Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Patients — Bristol-Myers Squibb
• Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy to Lenalidomide Alone in Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant — Celgene
• Study on the Dose, Safety, and Effectiveness of CC-220 Alone and with Other Treatments for Multiple Myeloma — Celgene
• Study on Mezigdomide and Elranatamab for Treating Relapsed or Hard-to-Treat Multiple Myeloma — Celgene
• Study on the Effectiveness and Safety of Ciltacabtagene Autoleucel — Janssen Research & Development, LLC
• Study on the Safety, Drug Levels, and Effectiveness of CC-92480 with Other Treatments for Relapsed or Refractory Multiple Myeloma — Bristol-Myers Squibb
• Study on Belantamab Mafodotin with Standard Treatment for Relapsed-Refractory Multiple Myeloma — GlaxoSmithKline
• Study on Cemsidomide and Dexamethasone for Treating Relapsed or Refractory Multiple Myeloma — C4 Therapeutics, Inc.
• Study on the Effects of Elranatamab, Daratumumab, and Lenalidomide Compared to a Standard Treatment in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant — Pfizer
• Study on Linvoseltamab for Newly Diagnosed Multiple Myeloma Patients Who Have Not Yet Received Treatment — Regeneron Pharmaceuticals
• Study on Using Genetically Modified T-Cells to Target Cancer Mutations in People with Metastatic Cancer — National Cancer Institute (NCI)
• Extension Study for Patients Continuing Venetoclax Treatment from Previous Trials — AbbVie
• At-Home Cancer Treatment Compared to In-Clinic Treatment for Patients with Advanced Cancer — Mayo Clinic
• Study on ATRA and Carfilzomib for Patients with Multiple Myeloma — The Methodist Hospital Research Institute
• Study on AZD0305 Alone or with Other Cancer Drugs for Treating Relapsed or Hard-to-Treat Multiple Myeloma — AstraZeneca
• Study on Belantamab Mafodotin or Daratumumab with Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma — PrECOG, LLC.
• Study Comparing Belantamab Mafodotin with Pomalidomide and Dexamethasone Versus Bortezomib with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma — GlaxoSmithKline
• Study on Bortezomib, Isatuximab, Cyclophosphamide, and Dexamethasone for Multiple Myeloma Patients Eligible for Transplant — Medical College of Wisconsin
• Study on CAR T-cell Therapy for Patients with Kidney Problems — Northside Hospital, Inc.
• Study on CAR-PRISM: Precision Intervention for High-Risk Smoldering Myeloma — Dana-Farber Cancer Institute
• Carfilzomib Treatment for Patients with Relapsed and Refractory Multiple Myeloma — Amgen
• Study Comparing Two Treatment Combinations for Newly Diagnosed Multiple Myeloma — University of Chicago
• Study on Cevostamab with Pomalidomide and Dexamethasone Compared to Standard Treatment for Previously Treated Multiple Myeloma — Hoffmann-La Roche
• Study on Zevor-cel (CT053) for Patients with Relapsed or Hard-to-Treat Multiple Myeloma — CARsgen Therapeutics Co., Ltd.
• COMbination Regimens in MM Post AHCT to ElimiNate MRD Utilizing IbERdomide — University of Alabama at Birmingham
• Combination Treatment Approaches for High-Risk Multiple Myeloma: REACH Trial — Mayo Clinic
• Comparing Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) with Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma — National Cancer Institute (NCI)
• Compassionate Use of REGN5458 for Patients with Difficult-to-Treat Multiple Myeloma — Regeneron Pharmaceuticals
• Study on DARA RVD for High-Risk Smoldering Multiple Myeloma — Omar Nadeem, MD
• Study on Daratumumab, Carfilzomib, Lenalidomide, and Low Dose Dexamethasone for Newly Diagnosed Multiple Myeloma — University of Chicago
• Study on Daratumumab, Carfilzomib, Pomalidomide, and Dexamethasone for Treating Relapsed and Resistant Multiple Myeloma — Andrew Yee, MD
• Early Access to Daratumumab Treatment for Patients with Relapsed or Hard-to-Treat Multiple Myeloma — Janssen Research & Development, LLC
• Early Access to Daratumumab Treatment for Patients with Relapsed or Hard-to-Treat Multiple Myeloma — Janssen Research & Development, LLC
• Study on Eliminating Minimal Residual Disease After Transplant in Multiple Myeloma Patients — Medical College of Wisconsin
• Study on Elotuzumab, Iberdomide, and Dexamethasone After Ide-Cel for Relapsed and Refractory Multiple Myeloma — Omar Nadeem, MD
• Study on Elranatamab for Relapsed/Refractory Multiple Myeloma — Massachusetts General Hospital
• Study on Elranatamab for Treating Relapsed or Hard-to-Treat Multiple Myeloma — University of California, San Diego
• Elranatamab Access Study for Patients with Multiple Myeloma — Pfizer
• Study on Using T-Cell Therapy to Improve Outcomes in Newly Diagnosed Myeloma Patients with Minimal Residual Disease — Noffar Bar
• Study on ERd Combination Treatment for Newly Diagnosed Multiple Myeloma — University of Miami
• Study Comparing Two Treatment Combinations for Relapsed or Refractory Multiple Myeloma — GlaxoSmithKline
• Expanded Access Program for Ciltacabtagene Autoleucel (Cilta-Cel) for Patients with Multiple Myeloma — Janssen Scientific Affairs, LLC
• Expanded Access Program for Patients Receiving Nonconforming Idecabtagene Vicleucel for Multiple Myeloma — Celgene
• Access to Venetoclax Before Official Approval — AbbVie
• Study on Iberdomide and Daratumumab as Maintenance Therapy After Stem Cell Transplant for Multiple Myeloma — Barbara Ann Karmanos Cancer Institute
• Iberdomide Maintenance Therapy for Patients with Multiple Myeloma — University of Nebraska
• Study on Effective and Cost-Conscious Maintenance Dosing of Daratumumab for Multiple Myeloma — Eden Biltibo
• Study on IDP-023 Alone and with Antibody Therapies for Advanced Blood Cancers — Indapta Therapeutics, INC.
• Study on Immuno-PRISM: Testing Teclistamab and Comparing with Lenalidomide + Dexamethasone for High-Risk Smoldering Multiple Myeloma — Irene Ghobrial, MD
• IMMUNOPLANT Study for Newly Diagnosed Multiple Myeloma — Dickran Kazandjian, MD
• Study on Isa-Pom-Dex for Elderly or Frail Patients with Relapsed or Refractory Multiple Myeloma — UNC Lineberger Comprehensive Cancer Center
• Study on Isa-Rd Treatment for Older or Frail Patients with Newly Diagnosed Multiple Myeloma — UNC Lineberger Comprehensive Cancer Center
• Study on Isatuximab During Stem Cell Collection and Transplant for Patients with Multiple Myeloma and Lymphoma — Divaya Bhutani
• Study on Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma — Massachusetts General Hospital
• Study on Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Newly Diagnosed Multiple Myeloma — Jacob Laubach, MD
• Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma — Medical College of Wisconsin
• Study on Ixazomib, Pomalidomide, and Dexamethasone for Relapsed or Refractory Multiple Myeloma — Omar Nadeem, MD
• Karyopharm Expanded Access Program for Selinexor — Karyopharm Therapeutics Inc
• Study on New Drug Combination for Transplant-Eligible Multiple Myeloma Patients — Massachusetts General Hospital
• Study on Lenalidomide and Melphalan for Stem Cell Transplant in Relapsed Multiple Myeloma — Weill Medical College of Cornell University
• Study on Linvoseltamab and Lenalidomide for Deepening Responses in Newly Diagnosed Multiple Myeloma — Dickran Kazandjian, MD
• Long-term Follow-up Study for Patients Treated with Genetically Modified T Cells — Autolus Limited
• Study on Elranatamab for Treating Multiple Myeloma Resistant to Certain Treatments — Pfizer
• Study on Elranatamab for Treating Multiple Myeloma That Has Returned After Previous Treatments — Pfizer
• Study on Elranatamab Alone or with Daratumumab Compared to Daratumumab, Pomalidomide, and Dexamethasone for Treating Relapsed or Refractory Multiple Myeloma — Pfizer
• Managed Access Program for Combination Treatment with Belantamab Mafodotin for Multiple Myeloma — GlaxoSmithKline
• Study on Using Elranatamab for Personalized Maintenance After Transplant in Multiple Myeloma Patients — Washington University School of Medicine
• Study on Melphalan, Prednisone, and Thalidomide or Lenalidomide for Newly Diagnosed Multiple Myeloma — National Cancer Institute (NCI)
• Study on Using Minimal Residual Disease to Delay Transplant in Multiple Myeloma Patients (MILESTONE) — University of Alabama at Birmingham
• Study on Using Mozobil for Stem Cell Transplantation — Thomas Jefferson University
• Study on Myeloablative Stem Cell Transplant with Donor for Blood Disorders — Masonic Cancer Center, University of Minnesota
• Study on Nivolumab for Multiple Myeloma Patients After Idecabtagene Vicleucel Treatment — Wake Forest University Health Sciences
• Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma — Yale University
• Study Comparing Two Treatment Combinations for Patients with Relapsed or Refractory Multiple Myeloma — Celgene
• Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma — SCRI Development Innovations, LLC
• Study on REGN5458 for Adults with Relapsed or Hard-to-Treat Multiple Myeloma — Regeneron Pharmaceuticals
• Phase 2 Study on Adaptive Treatment Strategy for Newly Diagnosed Multiple Myeloma Using Daratumumab-Based Therapy — University of Michigan Rogel Cancer Center
• Phase 3 Study of Teclistamab with Lenalidomide or Alone Versus Lenalidomide Alone for Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplant — Stichting European Myeloma Network
• Phase I/II Study of Belumosudil Mesylate Alone and with Dexamethasone for Relapsed/Refractory Multiple Myeloma — M.D. Anderson Cancer Center
• Phase I/II Study of CAR.70-Engineered IL15-Modified Cord Blood NK Cells with Chemotherapy for Treating Relapsed or Resistant Blood Cancers — M.D. Anderson Cancer Center

Looking for a program not shown above? Search the full catalog for “Multiple Myeloma” to see every match including additional filters.